#$%^&*AU2012202155B220140821.pdf#####62 ABSTRACT OF THE DISCLOSURE A method of chronically reducing a patients pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.